Cathy De Lara
After gaining my BSc in genetics from the University of Swansea I worked for the MRC’s Radiobiology unit at Harwell where I looked at different types of radiation and the damage they do to DNA.
After moving to the Jenner Institute in Compton I joined the Beverley group studying the turnover rates of different cell types in both healthy subjects and those infected with TB and HIV. I also gained my MSc in immunology from Kings in London.
In 2009 the Beverley group moved to the PMB and in 2011 I changed groups and now work for the Klenerman group where I am involved in several projects. Since working for Paul I have been involved in several RSV (Respiratory Syncytial virus) vaccine trials. I am now looking at the immune response to different HCV treatments in volunteers in the BOSON HCV treatment study.
First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on ChAd155 viral vector expressing RSV viral proteins F, N and M2-1 in healthy adults.
Cicconi P. et al, (2019), Clin Infect Dis
Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV).
McNaughton AL. et al, (2019), Sci Rep, 9
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
Green CA. et al, (2019), J Infect, 78, 382 - 392
Single-cell transcriptome analysis of CD8 + T-cell memory inflation.
Highton AJ. et al, (2019), Wellcome Open Res, 4
Humoral and cellular immunity to RSV in infants, children and adults.
Green CA. et al, (2018), Vaccine, 36, 6183 - 6190